功能性运动网络异常与帕金森病中的勒沃多巴诱导的运动障碍相关:系统性审查
Birgitte Liang Chen Thomsen1, Mikkel C Vinding2, David Meder1
1Danish Research Centre for Magnetic Resonance, Department of Radiology and Nuclear Medicine, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark.
NeuroImage. Clinical
|November 22, 2024
概括
在帕金森病中,Levodopa诱导的运动障碍 (LID) 涉及改变大脑活动和运动网络的连接. 功能性大脑映射显示皮质刺激性和可塑性的变化,指导LID的未来疗法.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 运动障碍 运动障碍
背景情况:
- 帕金森病 (PD) 治疗的乐伏多巴往往导致乐伏多巴诱导的动力障碍 (LID).
- 了解LID中运动网络的变化对于开发有效治疗非常重要.
- 功能性大脑映射技术为这些神经变化提供了洞察力.
研究的目的:
- 系统地审查和总结LID患者的运动网络异常,使用功能性大脑映射.
- 为了确定与LID相关的改变大脑活动和连接的常见模式.
主要方法:
- 对预先注册的研究进行系统审查 (PROSPERO:CRD42022320830).
- 包括使用功能性MRI,EEG,PET,SPECT或TMS的研究,其中至少有10名LID患者.
- 分析运动网络的变化,包括激活,功能连接,皮质刺激性和可塑性.
主要成果:
- 患有LID的患者在levodopa后表现出皮质区域和膜中的运动相关激活和功能连接性增加.
- 在右下额叶皮层观察到活性减少.
- 在LID患者中,TMS研究表明皮质刺激性升高和可塑性降低,一些抑制性TMS协议显示过渡的抗动效应.
结论:
- 列沃多巴诱导的运动障碍症的特征是运动网络功能,连接性,兴奋性和可塑性的广泛变化.
- 尽管研究规模和复制的局限性,但研究结果强调了LID的复杂神经基础.
- 对这些网络变化的进一步研究对于推进针对性,基于刺激的LID疗法至关重要.
相关概念视频
Parkinson's Disease: Treatment
220
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
220
Parkinson's Disease: Overview
482
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
482
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
259
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
259


